



THE LUNDQUIST
INSTITUTE

Internal Control and Compliance Reports
June 30, 2025

CONTENTS

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	1-2
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance	3-6
Schedule of Expenditures of Federal Awards.....	7-17
Notes to the Schedule of Expenditures of Federal Awards.....	18
Schedule of Findings and Questioned Costs	19-20
Summary Schedule of Prior Year Audit Findings.....	21-22

**INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER
FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS
BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN
ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS***

To the Board of Directors of
the Lundquist Institute for Biomedical Innovation
at Harbor-UCLA Medical Center

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (the Institute), which comprise the statement of financial position as of June 30, 2025, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated January 6, 2026.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Institute's internal control over financial reporting (internal control) as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, we do not express an opinion on the effectiveness of the Institute's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies in internal control, such that there is a reasonable possibility that a material misstatement of the Institute's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies, and therefore, material weaknesses or significant deficiencies may exist that were not identified. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Institute's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Institute's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Institute's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

A handwritten signature in cursive script that reads "Windes, Inc.".

Long Beach, California
January 6, 2026

**INDEPENDENT AUDITORS' REPORT ON COMPLIANCE FOR EACH MAJOR
FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE;
AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED
BY THE UNIFORM GUIDANCE**

To the Board of Directors of
the Lundquist Institute for Biomedical Innovation
at Harbor-UCLA Medical Center

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's (the Institute) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Institute's major federal programs for the year ended June 30, 2025. The Institute's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Institute complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2025.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Institute and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Institute's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Institute's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Institute's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Institute's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Institute's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Institute's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit, we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the Institute as of and for the year ended June 30, 2025, and have issued our report thereon dated January 6, 2026, which contained an unmodified opinion on those financial statements. Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Winder, Inc.

Long Beach, California
January 6, 2026

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES				
<i>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASE</i>				
Novel Toxins and Receptors in Mucormycosis Pathogenesis	93.855	5R01AI063503-19	\$ 728,571	\$ -
Short and Long Term Outcomes of Doxycycline Versus TMP-SMX f	93.855	5U01AI116400-05	1,553,551	329,853
The Role of Purine Biosynthesis and Stringent Response in Pe	93.855	5R01AI139244-05	271,676	-
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority	93.855	5R01AI41202-05	132,139	-
Transcriptional Networks Governing A. Fumigatus Virulence	93.855	5R01AI162802-05	645,558	202,171
Targeting Evolutionarily Acquired Insertion Sequences in Candida	93.855	5R21AI169276-02	106,123	24,932
Systems Epigenomics of Persistent Bloodstream Infection	93.855	1U19AI172713-01	85,508	85,508
Systems Epigenomics of Persistent Bloodstream Infection	93.855	5U19AI172713-02	265,139	-
Systems Epigenomics of Persistent Bloodstream Infection	93.855	5U19AI172713-02	547,096	121,017
Systems Epigenomics of Persistent Bloodstream Infection	93.855	5U19AI172713-02	340,478	-
Systems Epigenomics of Persistent Bloodstream Infection	93.855	5U19AI172713-02	926,907	926,907
Systems Epigenomics of Persistent Bloodstream Infection	93.855	5U19AI172713-03	5,653	-
Systems Epigenomics of Persistent Bloodstream Infection	93.855	5U19AI172713-03	14,890	-
Systems Epigenomics of Persistent Bloodstream Infection	93.855	5U19AI172713-03	5,077	-
Asthmatic Inflammation Requires Neuronal Upregulation of B-c	93.855	1R56AI175328-01A1	256,861	15,000
Delineating Host Response to Central Venous Catheter Association	93.855	1R21AI178352-01A1	253,516	15,930
Delineating Host Response to Central Venous Catheter Association	93.855	5R21AI178352-02	38,863	7,555
Role of Multi-Drug Resistant Candida Auris Hyr1 / Iff-like P	93.855	5K01AI180591-02	127,464	-
Novel Toxins and Receptors in Mucormycosis Pathogenesis	93.855	5R01AI063503-17	5,724	-
Cross-Kingdom Vaccine Targeting Healthcare-Associated Pathogens	93.855	3R01AO141202-05S1	2,687	-
Targeting the Regulatory Mechanism of Hyphae to Lateral Yeast Growth	93.855	5R01AI141794-04	64,368	-
<i>Pass Through: University of California, Los Angeles</i>				
ACTG - Protocol Implementation Fund	93.855	1560 B YC395	69,535	-
AIDS Prevention and Treatment Clinical Trials Unit ("ACTG")	93.855	15680000084237	351,523	-
<i>Pass Through: Dartmouth College</i>				
Membrane-Active Quinoline and Quinazoline Antibacterials	93.855	R1722	25,670	-
<i>Pass Through: Duke University</i>				
A Phase 2b, Multicenter, Protocol 20-0002 - Trial #ARLG2 DOT2	93.855	A034260, SPS-261113	5,756	-
<i>Pass Through: Benaroya Research Institute at Virginia Mason</i>				
Efficacy of Belimumab and Rituximab Compared to Rituximab AI	93.855	FY22ITN329, FY23ITN329	4,172	-
<i>Pass Through: University of California, Los Angeles</i>				
A Phase III Randomized, Double-Blind, Placebo-Controlled Mul	93.855	1560 B XB592	534,640	-
Multi-Dimensional Outcome Prediction Algorithm for Hospital	93.855	15530000078480	49,797	-
<i>Pass Through: Institute for Clinical Research, Inc</i>				
Admin/start up ACTIV-3...Investigational Therapeutics for Home	93.855	M89-LU-066-2012-9	12,125	-
<i>Pass Through: National Jewish Medical and Research Center</i>				
COPD FND_COPD Gene (Genetic Epidemiology of COPD)	93.855	20303601	137,063	-
<i>Pass Through: University of Washington</i>				
Role of Sialoglycan Binding in the Pathogenesis of Streptococcus	93.855	UWSC15939-PO-0100134397	57,811	-
<i>Pass Through: University of Nevada Reno</i>				
Multiplexed Rapid Immunoassay for Invasive Fungal Disease	93.855	UNR-21-29-AMND 04	191,177	-
<i>Pass Through: University of Iowa, College of Medicine</i>				
Systematic Genetic Analysis of C. Albicans CNS Infection	93.855	S04064-01	8,090	-
Regulation of Candida Albicans Pathogenesis by Protein Kinases	93.855	S04783-01	199,350	-

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<u>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASE (CONTINUED)</u>				
<i>Pass Through: Institute for Clinical Research, Inc</i>				
INSIGHT 18 -STRIVE-ADMINISTRATIVE	93.855	M89-LU-066-2012-9	5,607	-
<i>Pass Through: University of Iowa, College of Medicine</i>				
Novel Mechanisms of Azole Resistance in Clinical Isolates	93.855	S04851-01	111,013	-
<i>Pass Through: University of Georgia</i>				
Roles of C. Albicans White-Opaque Regulators in Biofilm	93.855	SUB00003555	100,937	-
<i>Pass Through: University of Wisconsin Madison</i>				
Quantitative Genetic Approaches to Candida Albicans Pathogen	93.855	0000003567	123,908	-
<i>Pass Through: Duke University</i>				
RECOVER-ENERGIZE	93.855	OT2HL156812-01	21,892	-
<i>Pass Through: Brigham and Women's Hospital</i>				
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomi	93.855	Agmt Dated 9/13/24	69,099	-
<i>Pass Through: Duke University</i>				
Protocol: OPTIMIZE-GNI 23-0013 (DMID)	93.855	WBSE- 303003018 SPS-28714	4,687	-
<i>Pass Through: University of California, Los Angeles</i>				
Advancing Clinical Therapeutics Globally for HIV/AIDS and Ot	93.855	15600000256831	21,106	-
<i>Pass Through: University of California, Los Angeles</i>				
AIDS Prevention and Treatment Clinical Trials Unit ("ACTG")	93.855	15680000084237 (former 156	290,524	-
<i>Pass Through: Institute for Clinical Research, Inc</i>				
Patient Care ACTIV-3, ...Investigational Therapeutics for Home	93.855	M89-LU-066-2012-9	90,699	-
<i>Pass Through: Institute for Clinical Research, Inc</i>				
EPOC INSIGHT 017	93.855	M89-LU-066-2012-9	11,737	-
<i>Pass Through: University of California, Los Angeles</i>				
UCLA-CDU CFAR	93.855	1559 G LA970	20,902	-
<i>Pass Through: University of Maryland</i>				
Host Pathogen Interactions During Mucormycosis	93.855	18496 Req:2107	55,640	-
<i>Pass Through: University of Minnesota</i>				
Aneuploidy and Acquired Antifungal Drug Resistance in Candida	93.855	N008184001	37,590	-
<i>Pass Through: University of Texas Health Science Center at San Antonio</i>				
Therapeutic Testing in Murine Models of Fungal Infections	93.855	175329/173741	74,053	-
<i>Pass Through: University of California, Los Angeles</i>				
AEC At-Large	93.855	15600000025169	11,998	-
<i>Pass Through: Charles R. Drew University of Medicine and Science</i>				
Novel Metabolic Reprogramming Strategy for the Treatment of	93.855	G0077320	1,408	-
			9,077,358	1,728,873
<u>NATIONAL CANCER INSTITUTE</u>				
Deciphering Functions of the ATR-METTL3-BRCA1 Axis in Genome	93.393	5R01CA288736-02	404,772	-
<i>Pass Through: Fred Hutchinson Cancer Research Center</i>				
Life and Longevity After Cancer (LILAC): The Women's Health	93.393	0001127741	5,110	-
<i>Pass Through: University of California, Los Angeles</i>				
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction	93.393	1700 G ZA281	36,021	-
			445,903	-

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<u>NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT</u>				
Contraceptive Clinical Trials Network (CCTN) Male Sites	93.865	75N94020D00007	35,681	-
Epitranscriptomic Regulation of Spermatogenesis and Male Fertility	93.865	5R01HD099924-05	70,559	-
Celebrating the Inspired and Inspiring Testis Biology - The X	93.865	1R13HD115366-01	10,000	-
Disparities in the Effect of State Policy for the Newborn Sc	93.865	5R21HD105170-02	5,328	-
Epitranscriptomic Regulation of Spermatogenesis and Male Fertility	93.865	5R01HD099924-04	235	-
IND-Enabling Studies to Develop Triptonide Into the First No	93.865	1R61HD114186-01	198,789	10,000
TO 7/CCN-017 Nestorone Gel and Testosterone Gel	93.865	HHSN27500007	418,361	180,492
Maternal Obesity Programs Offspring Hypothalamic Neurogenesis	93.865	5R01HD099813-04	665,206	185,235
Tryptophan Metabolism and its Role in Fibroid Pathogenesis	93.865	5R01HD109286-04	478,364	-
PROJ 2: Basic Research - Mechanism Underlying the Transduction	93.865	5P50HD098593-04	29,186	19,216
Tryptophan Metabolism and its Role in Fibroid Pathogenesis	93.865	5R01HD109286-02	13,149	-
TO 2 /DMAU-SEDDS Study	93.865	HHSN27500002	1,033	-
TO 2/ DMAU-SEDDS Hormone Measurement	93.865	HHSN27500002	4,729	-
LAB - Clinical Evaluation of Nestorone Gel and Testosterone G	93.865	HHSN27500007	94,914	-
Mechanism of Long Non-coding RNAs Action in Leiomyoma	93.865	5R01HD100529-04	168,254	-
PROJ 1: Diet and Exercise Modulate the Sperm Epigenome in Men	93.865	5P50HD098593-05	133,065	-
PROJ 2: Basic Research - Mechanism Underlying the Transduction	93.865	5P50HD098593-05	195,416	-
ADMIN CORE	93.865	5P50HD098593-05	14,790	-
ANIMAL CORE	93.865	5P50HD098593-05	48,577	-
OUTR/EDUCATION CORE	93.865	5P50HD098593-05	36,316	-
EPIGENOMICS CORE	93.865	5P50HD098593-05	37,600	-
PROJ 3:Germline-mediated Transgenerational Epigenetic Inheritance	93.865	5P50HD098593-05	322,927	322,927
<i>Pass Through: SRI International</i>				
Quantitative Analysis of DMAU and DMA in Rat Serum Samples	93.865	PO97967	35,510	-
<i>Pass Through: Women & Infants Hospital of Rhode Island</i>				
Neonatal Neurobehavior and Outcomes in Pre-term Infants	93.865	9373	8,812	-
<i>Pass Through: Oregon Health & Science University</i>				
Clinical and Genetic Analysis of Retinopathy of Prematurity	93.865	1016626_LUNDQUIST	32,735	-
			3,059,536	717,870
<u>NATIONAL INSTITUTE OF DIABETES, DIGESTIVE, AND KIDNEY DISEASE</u>				
Spatiotemporal Regulation of Human Islet Organogenesis	93.847	5R01DK136888-02	295,224	-
Plant-Focused Nutrition in Patients with Diabetes and Chronic Illness	93.847	5R01DK132875-03	266,619	25,188
<i>Pass Through: Wake Forest University</i>				
Genetic and Epidemiological Predictors - Pym fr NC Hospital	93.847	63-45102-10000550024	23,279	-
<i>Pass Through: Drexel University</i>				
Social Determinants of Fatty Liver Disease and its Racial	93.847	900307	171,780	-
<i>Pass Through: Vanderbilt University Medical Center</i>				
Virtual Systemic Identification of Drug Targets of Obesity	93.847	VUMC111731	16,513	-
Virtual Systemic Identification of Drug Targets of Obesity	93.847	VUMC111731	790	-
<i>Pass Through: Beth Israel Deaconess Medical Center, Inc</i>				
Metabolomic Predictors of Insulin Resistance and Diabetes	93.847	01063766	33,043	-
Metabolomic Predictors of Insulin Resistance and Diabetes	93.847	01063766	11,904	-

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<u>NATIONAL INSTITUTE OF DIABETES, DIGESTIVE, AND KIDNEY DISEASE (Continued)</u>				
<i>Pass Through: University of California, San Diego</i>				
Diabetes Research Center (DRC)	93.847	704299	70,553	70,553
Diabetes Research Center (DRC)	93.847	704299	209,948	68,000
dkNET Coordinating Unit: An Information Network for FAIR Res	93.847	705877	2,540	-
<i>Pass Through: University of Michigan</i>				
NEPTUNE Public-Private Partnership (MATCH Study)	93.847	SUBK00016559, Match Study	1,408	-
<i>Pass Through: Massachusetts General Hospital</i>				
TOPMed Omics of Type 2 Diabetes and Quantitative Traits	93.847	238171	39,660	-
TOPMed Omics of Type 2 Diabetes and Quantitative Traits	93.847	GR0238171-S09	35,124	-
Longitudinal Omics-Based Trajectories of Type 2 Diabetes Sub	93.847	246078	75,168	-
<i>Pass Through: University of California, Los Angeles</i>				
Hybrid Closed Loop Insulin Pump Use in Poorly Controlled Type	93.847	15550000110068	12,936	-
A Randomized Controlled Trial of Thyroid Hormone Supplementation	93.847	15640000144310	49,343	-
A Randomized Controlled Trial of Thyroid Hormone Supplementation	93.847	15640000144310	10,156	-
A Randomized Controlled Trial of Thyroid Hormone Supplementation	93.847	15640000144310	73,140	-
A Randomized Controlled Trial of Thyroid Hormone Supplementation	93.847	15640000144310	95,120	-
Training Core	93.847	1562 G LA904	69,308	-
Continuous Glucose Monitoring in Dialysis Patients to Overcome Diabetes	93.847	7R01DK132869-02	11,807	-
Training Core	93.847	15620000213280	88,507	-
LIFT-UP	93.847	15550000144496	16,348	-
KUH-ART: Advanced Research Training in Kidney Disease, Urolo	93.847	1652 G ZA119	20,075	-
KUH-ART: Advanced Research Training in Kidney Disease, Urolo	93.847	16520000176063	20,075	-
<i>Pass Through: University of North Carolina at Chapel Hill</i>				
Integrative Approaches to Identifying Function and Clinical	93.847	5119491	5,035	-
Integrative Approaches to Identifying Function and Clinical	93.847	5119491	26,268	-
<i>Pass Through: University of Pennsylvania</i>				
CureGN-Penn PCC (Formerly PROGRESS)	93.847	500923	16,302	-
<i>Pass Through: Indiana University</i>				
Collaborative Clinical Research on Nonalcoholic Steatohepatitis	93.847	10281-LI	51,383	-
<i>Pass Through: Stanford University</i>				
Novel Incidental Calcium Evaluation (NICE) Registry	93.837	63625788-209311	74,539	-
			1,893,895	163,741
<u>NATIONAL INSTITUTE OF DENTAL AND CRANOFACIAL RESEARCH</u>				
Oral Commensal Fungi and Structural Immunity	93.121	5R01DE031382-04	34,936	-
Oral Commensal Fungi and Structural Immunity	93.121	5R01DE031382-02	2,421	-
Oral Commensal Fungi and Structural Immunity	93.121	5R01DE031382-03	666,340	88,480
			703,697	88,480
<u>NATIONAL INSTITUTE OF ALCOHOL ABUSE AND ALCOHOLISM</u>				
<i>Pass Through: Boston University</i>				
Trans-omic Analysis of Alcohol Consumption and its Relation	93.273	4500003941	10,037	-
			10,037	-

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<i>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</i>				
Coronary Artery Calcium, Aortic Calcification, and Density in	93.837	5R01HL146666-04	46,148	46,148
Type I IFN Signaling During Lung Development in Down Syndrome	93.837	5R01HL155104-01A1	24,656	20,441
Determinants of 5 Year Progression of Muscle Dysfunction	93.838	5R01HL151452-04	229,551	60,599
E-Cigarette Vaping During Pregnancy and Lactation, Germ Cell	93.838	5R01HL151769-04	193,984	9,692
Type I IFN Signaling During Lung Development in Down Syndrome	93.838	3R01HL155104-01A1S1	63,076	-
Type I IFN Signaling During Lung Development in Down Syndrome	93.838	5R01HL155104-03	498,987	87,494
Type I Interferon Regulates Angiogenesis in Down Syndrome	93.838	5R21HL165411-02	76,078	-
Type I Interferon Regulates Angiogenesis in Down Syndrome	93.838	3R21HL165411-02S1	20,641	-
Novel Cardiopulmonary Exercise Testing (CPET) Variables	93.838	5R01HL166850-03	678,940	-
Cellular Senescence in Trisomy 21 Lung Disease	93.838	5R01HL171915-02	469,033	120,368
Novel Cardiopulmonary Exercise Testing (CPET) Variables	93.838	1R01HL166850-01A1	121,010	-
<i>Pass Through: Mount Sinai</i>		0255-1911-4609 /		
Application of Machine Learning to Identify Obstructive Sleep	93.233	1F129091093-940002	162,342	-
<i>Pass Through: Wayne State University</i>				
Improving Outcomes for Patients with SDB and Insufficient Sleep	93.233	WSU24060	2,036	-
<i>Pass Through: University of Washington</i>				
CHARGE Consortium: Gene Discovery for CVD and Aging Phenotype	93.837	UWSC14004	17,456	-
<i>Pass Through: Massachusetts General Hospital</i>				
TOPMed Omics of Cardiovascular Disease in Diabetes	93.837	236957	72,950	-
The Role of Arylsulfatase in Vascular Calcification	93.837	242913	21,253	-
REPRIEVE (A5332) Ref #113122 or (224978)	93.837	224978	1,808	-
The Role of Arylsulfatase in Vascular Calcification	93.837	GR0242913-S02	5,435	-
<i>Pass Through: University of Texas Health Science Center at Houston</i>				
Genetic Architecture of Cardiac Structure and Function	93.837	SA0002996	31,069	-
Whole-Genome Sequencing Analysis Of Coronary Atherosclerosis	93.837	SA0000630	39,952	-
<i>Pass Through: University of California, Los Angeles</i>				
("MWCCS CORE") Los Angeles CRS for the MACS/WHS Combined Cohort	93.837	0000219764	136,003	-
("MWCCS S1") Los Angeles CRS for the MACS/WHS Combined Cohort	93.837	0000219764	22,797	-
("MWCCS S2") Los Angeles CRS for the MACS/WHS Combined Cohort	93.837	0000219764	6,675	-
Los Angeles CRS for the MACS/WHS Combined Cohort Study	93.837	1935 G XA748	210	-
("MWCCS CORE") Los Angeles CRS for the MACS/WHS Combined Cohort	93.837	0000219764	408,228	-
("MWCCS S1") Los Angeles CRS for the MACS/WHS Combined Cohort	93.837	0000219764	215,394	-
("MWCCS S2") Los Angeles CRS for the MACS/WHS Combined Cohort	93.837	0000219764	21,942	-
UCLA-UCI Center for Eliminating Cardio-Metabolic Disparities	93.837	15570000312996	40,905	-
UCLA-UCI Center for Eliminating Cardio-Metabolic Disparities	93.837	15570000298290	4,023	-
<i>Pass Through: Boston University</i>				
Mitochondrial DNA, Nuclear DNA Methylation, and Cardiometabolic Health	93.837	4500004971	2	-
Mitochondrial DNA, Nuclear DNA Methylation, and Cardiometabolic Health	93.837	4500005101	30,868	-
<i>Pass Through: Washington University - St. Louis, MO</i>				
A Multi-Ancestry Study of Gene-Lifestyle Interactions	93.837	WU-24-0541/PO ST00021661	34,166	-
<i>Pass Through: University of Michigan</i>				
1/2 ICECAP: Influence of Cooling Duration on Efficacy in Cardiac Arrest	93.837	SUBK00013201- 003/SUBK00013195 (Master Trial Agreement Ref. #)	7,331	-

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<i>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (CONTINUED)</i>				
<i>Pass Through: University of North Carolina at Chapel Hill</i>				
	93.837	5127668	25,504	-
	93.837	5127668	16,982	-
<i>Pass Through: Duke University</i>				
	93.837	303003196	15,410	-
<i>Pass Through: The University of Texas Health Science Center at Houston</i>				
	93.837	SA0002834	57,818	-
	93.837	SA0002834	15,806	-
<i>Pass Through: Beth Israel Deaconess Medical Center, Inc.</i>				
	93.837	GRT66272	11,100	-
	93.837	GRT66272	6,590	-
<i>Pass Through: Tufts University</i>				
	93.837	EP0238925	41,918	-
<i>Pass Through: GE HealthCare Technology and Innovation Center</i>				
	93.837	PO H37810000799819-replaces PO 401187768	418,128	-
<i>Pass Through: University of Illinois at Chicago</i>				
	93.837	18824	636,764	-
<i>Pass Through: Kaiser Permanente Research Institute</i>				
	93.837	RNG210798-LI-04	7,858	-
<i>Pass Through: Cedars-Sinai Medical Center</i>				
	93.837	0002067970	27,217	-
<i>Pass Through: University of Texas Health Science Center at San Antonio</i>				
	98.837	175523/175514	747,527	-
	93.837	175516/175514	379,250	-
<i>Pass Through: Advent Therapeutics, Inc.</i>				
	93.837	R44HL142353	2,958	-
	93.838	5R44HL142353-05 (Lundquist #32676-01)	508,531	-
<i>Pass Through: Ohio State University Medical Center</i>				
	93.838	SPC-1000012716 GR132827	59,026	2,924
	93.838	SPC-1000014140 GR137172	138,528	6,702
<i>Pass Through: Mayo Clinic</i>				
	93.838	LUN-299544-03	74,066	-
<i>Pass Through: Allerdia, Inc</i>				
	93.838	All-03	258,993	-
	93.838	All-02	40,276	-
<i>Pass Through: Columbia University</i>				
	93.838	2(GG015835-04)	592	-
<i>Pass Through: University of Alabama Birmingham</i>				
	93.838	000528895-SC001	215	-
	93.838	000528895-SC001 A03	66,320	-
	93.838	000528895-SC001 A03	27,542	-

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<i>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (CONTINUED)</i>				
<i>Pass Through: New York University School of Medicine</i>				
1/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed	93.839	21-A2-00-1004666	2,720	-
1/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed	93.839	21-A2-00-1004666	76,684	-
<i>Pass Through: University of Washington</i>				
Links Between Cardiovascular Disease, Lung Disease, and Obstruction	93.839	UWSC14131	2,134	-
<i>Pass Through: Duke University</i>				
RECOVER-VITAL Platform Protocol for Evaluation of Intervention	93.RD	WBSE: 383000909; SPS: 280176	30,976	-
RECOVER-NEURO: A Platform Protocol for Evaluation of Intervention	93.RD	383001279 (SPS 281174)	55,316	-
<i>Pass Through: University of Washington</i>				
Multi-Ethnic Study of Atherosclerosis (MESA) - Coordinating	93.RD	UWSC16511	15,130	-
			<u>7,472,828</u>	<u>354,368</u>
<i>NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE</i>				
Defining Cerebellar Pathophysiology in Ataxia Telangiectasia	93.853	5R01NS131646-02	108,681	-
Defining Cerebellar Pathophysiology in Ataxia Telangiectasia	93.853	1R01NS131646-01A1	426,689	-
<i>Pass Through: RAND Corporation</i>				
Implementation and Evaluation of a Video-Based Prospective F	93.226	SCON-00000226	2,057	-
<i>Pass Through: University of California, San Diego</i>				
A Practice-Based Intervention to Improve Care for a Diverse	93.226	705213	47,550	-
<i>Pass Through: University of Southern California</i>				
OpenNerve Platform for Post-Stroke Dysphagia and Aspiration	93.310	SCON-00007161	15,329	-
<i>Pass Through: University of Minnesota</i>				
Lysosomal Disease Network	93.853	SUBA00000979-N008333301	52,499	-
<i>Pass Through: University of Michigan</i>				
Patterns of Survivors' Recovery Trajectories in the ICECAP T	93.853	SUBK00021673	485	-
<i>Pass Through: University of California, Los Angeles</i>				
Southwest Strategies to Innovate Emergency Care Clinical Trial	93.853	15350000105198	188,812	-
<i>Pass Through: University of Minnesota</i>				
Lysosomal Disease Network	93.853	N008333301	8,605	-
<i>Pass Through: Children's Hospital of Los Angeles</i>				
Pediatric Dose Optimization for Seizures in EMS (PediDOSE)	93.853	000016167-A	37,629	-
			<u>888,336</u>	-
<i>NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES</i>				
<i>Pass Through: University of California, Los Angeles (CTSI)</i>				
Clinical Translation Science Institute-Administrative Core	93.350	17900000087923	8,576	-
Clinical Translational Science Institute-Informatics Core	93.350	17900000087923	13,028	-
Clinical Translational Science Ins-Community and Collaboration	93.350	17900000087923	6,361	-
CTSI-Translational Endeavors: Workforce Development	93.350	17900000087923	1,313	-
CTSI-Research Methods: BioStats Epidemiology (BERD)	93.350	17900000087923	1,141	-
CTSI-Research Methods: Regulatory Knowledge and Support (RKS)	93.350	17900000087923	3,258	-
CTSI-Hub Research Capacity: Clinical Interactions (PCI)	93.350	17900000087923	12,434	-
CTSI-Network Capacity (LTIC)	93.350	17900000087923	8,541	-

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<i>NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (Continued)</i>				
CTSI - Optical - Precision Health	93.350	1790000087923	3,523	-
CTSI - Optical - Population Health	93.350	1790000087923	1,122	-
J. NRSA Training Core	93.350	1790000297263	4,282	-
Clinical Translation Science Institute-Administrative Core	93.350	1790000087923	143,442	-
Clinical Translational Science Institute-Informatics Core	93.350	1790000087923	215,708	-
Clinical Translational Science Ins-Community and Collaboration	93.350	1790000087923	131,254	-
CTSI - Translational Endeavors: Workforce Development	93.350	1790000087923	48,365	-
CTSI - Translational Endeavors: Pilot Translation and Clinical	93.350	1790000087923	23,149	-
CTSI - Research Methods:BioStats Epidemiology (BERD)	93.350	1790000087923	146,130	-
CTSI - Research Methods: Regulatory Knowledge and Support (RKS)	93.350	1790000087923	50,158	-
CTSI - Hub Research Capacity - Special Populations	93.350	1790000087923	29,042	-
CTSI - Hub Research Capacity: Clinical Interactions (PCI)	93.350	1790000087923	161,263	-
CTSI - Network Capacity (LTIC)	93.350	1790000087923	103,220	-
CTSI - Optical - Precision Health	93.350	1790000087923	38,289	-
CTSI - Optical - Population Health	93.350	1790000087923	12,346	-
Project 2: CTSI-Lundquist Precision Health Coordinator Pilot	93.350	1790 G LA025	11,127	-
Identification of Novel Virulence Factors on Multi-Drug Resistance	93.350	1790000087854	14,316	-
Personalized End of Life Care in Safety-Net Hospitals: Implementation	93.361	1562000066838	66,946	-
			<u>1,258,334</u>	<u>-</u>
<i>HEALTH RESOURCES AND SERVICES ADMINISTRATION</i>				
<i>Pass Through: University of California, San Francisco</i>				
AHEC: California Area Health Education Center	93.107	14034sc	128,504	-
<i>Pass Through: University Hospitals Cleveland Medical Center</i>				
Center for Pediatric Everyday Readiness - Regional Pediatric	93.110	WS #2021-1016	249,336	6,420
PySTART Training for Center for Pediatric Every Readiness	93.110	WS #2021-1016/Amend3	116,722	-
PySTART Training for Center for Pediatric Every Readiness	93.110	WS #2021-1016/Amend5	76,469	-
Pilot	93.110	WS #2021-1016/Amend3	46,506	-
<i>Pass Through: Seattle Children's Research Institute</i>				
STELAR: Seattle-Texas-Los Angeles Research Node PECARN	93.127	13536SUB	2,737	-
STELAR: Seattle-Texas-Los Angeles Research Node PECARN	93.127	13291SUB	2,195	-
<i>Pass Through: Oregon Health & Science University</i>				
EMSC Targeted Issue Grants	93.127	US DHHS/Health Resources & Services Admin. (850100)	863	-
<i>Pass Through: The University Of Texas Health Science Center</i>				
Emergency Medical Services for Children Innovation and Improvement	93.127	UTA20-000620/UTAUS-SUB00000270AM3	240,286	17,369
			<u>863,618</u>	<u>23,789</u>
<i>NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES</i>				
<i>Pass Through: Seattle Children's Research Institute</i>				
TIDES III: Endocrine Disruption, Hormones, and Sex Difference	93.113	12948SUB	87,002	-
			<u>87,002</u>	<u>-</u>

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<u>NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES</u>				
<i>Pass Through: University of Washington</i>				
Novel Statistical Inference for Biomedical Big Data	93.859	UWSC12322	6,082	-
			<u>6,082</u>	<u>-</u>
<u>NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH</u>				
<i>Pass Through: Loma Linda University Health</i>				
Unravelling Lung Interoception and its Functional Consequences	93.213	R01AT011691	42,572	-
			<u>42,572</u>	<u>-</u>
<u>NATIONAL INSTITUTE OF MENTAL HEALTH</u>				
Behavioral and Brain Network Effects of Dysfunction	93.242	5R21MH126359-02	21,659	9,863
Suicidal Behavior Among Adolescents Experiencing Homelessness	93.242	1R21MH137745-01	253,596	16,147
<i>Pass Through: The University of California, Los Angeles</i>				
Novel Radial Diffusion-Weighted MR Spectroscopic Imaging	93.242	16850000241115	14,633	-
			<u>289,888</u>	<u>26,010</u>
<u>NATIONAL INSTITUTES OF HEALTH</u>				
BRC Modernization of Sterilizing Equipment	93.351	1R24OD037736-01	76,703	-
Prevention of Obesity in Infants of Overweight and Obese Women	93.865	5R21HD104028-02	21,216	-
<i>Pass Through: University of Washington</i>				
Improving Linguistic Health Equity in Prehospital Emergency	93.307	UWSC15749	49,631	-
<i>Pass Through: Beth Israel Deaconess Medical Center, Inc.</i>				
Using Polygenic Risk Scores and Omics to Study How Suboptima	93.866	GRT65860	80,832	-
<i>Pass Through: University of California, Los Angeles</i>				
An Integrated Intervention Using a Pill Ingestible Sensor	93.307	13500000067404	488,181	-
UCLA Clinical Translational Science Institute	93.866	17900000087904	58,886	-
Pitavastatin to Reduce Physical Function Impairment and Frai	93.866	1560 B XB592	35	-
<i>Pass Through: Indiana University</i>				
Autosomal Dominant Osteopetrosis: A Natural History Study	93.846	10111	25,258	-
<i>Pass Through: University of Texas Health Science Center at San Antonio</i>				
Genetic Risk for Trajectories of Cognitive Decline and Progression	93.866	171921/171920	15,339	-
<i>Pass Through: University of Massachusetts Amherst</i>				
Metabolomic Profile of Chronic Distress in Relation to Disease	93.866	017425-9177	129,738	-
<i>Pass Through: University of California, San Francisco</i>				
The Care Ecosystem Response to COVID-19: Accelerating	93.866	13730sc	394,711	-
<i>Pass Through: Johns Hopkins University</i>				
Mitochondrial Function and Multiomics in Aging-Related Disease	93.866	2006808474	38,362	-
<i>Pass Through: Wake Forest Institute for Regenerative Medicine</i>				
Subclinical Vascular Contributions to Alzheimer's Disease: T	93.866	2512-33364-11000002967	242,009	-
			<u>1,620,901</u>	<u>-</u>
<u>CENTERS FOR DISEASE CONTROL AND PREVENTION</u>				
<i>Pass Through: American Association of Clinical Endocrinology</i>				
Improving Adult Immunizations in Adult Patients	93.185	6NH231P922656-01-01	136,627	-
			<u>136,627</u>	<u>-</u>

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

Federal Grantor/Pass-Through Grantor	Assistance Listing	Agency or Pass-Through Number	Federal Expenditures	Subcontract Expenditures
RESEARCH AND DEVELOPMENT CLUSTER (Continued)				
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (Continued)				
<i>IMMEDIATE OFFICE OF THE SECRETARY OF HEALTH AND HUMAN SERVICES</i>				
<i>Pass Through: New York University School of Medicine</i>				
Western Regional Alliance for Pediatric Emergency Management	93.889	11609sc	119,310	-
			<u>119,310</u>	<u>-</u>
<i>NATIONAL INSTITUTE ON DRUG ABUSE</i>				
<i>Pass Through: Cedars-Sinai Medical Center</i>				
1/24 Healthy Brain and Child Development National Consortium	93.279	0002296253	8,042	-
1/24 Healthy Brain and Child Development National Consortium	93.279	CSPO544088	80,082	-
<i>Pass Through: New York University School of Medicine</i>				
NIDA Clinical Trials Network: New Your Node	93.279	23-A0-S2-003671	397,984	-
			<u>486,108</u>	<u>-</u>
<i>NATIONAL HUMAN GENOME RESEARCH INSTITUTE</i>				
<i>Pass Through: Broad Institute</i>				
Development of Polygenic Scores for Diabetes and Complications	93.172	5001167-5500001688	19,736	-
			<u>19,736</u>	<u>-</u>
			28,481,768	3,103,131
U.S. DEPARTMENT OF COMMERCE				
Bioscience Research Training for Underserved Populations	11.617	60NANB24D239	266,297	-
			<u>266,297</u>	<u>-</u>
U.S. DEPARTMENT OF TRANSPORTATION				
Operationalization of Data Dashboards to Boost LA County	20.616	15350000357768/199013150	509,481	-
Evaluating the Effectiveness of a Novel EMS Mobile App	20.216	15350000357762	171,258	-
			<u>680,739</u>	<u>-</u>
U.S. DEPARTMENT OF DEFENSE				
IND-Enablement of Kinocidin γ -RP-1 for MDR Gram-Negative Inf	12.420	W81XWH2010133	600,918	-
A New Treatment for Heritable Pulmonary Artery Hypertension	12.420	W81XWH2010181	33,950	32,315
Investigating Novel Targetable Vulnerabilities of LAM Disease	12.420	W81XWH2211029	46,192	-
Wearable Multiplex Biosensors to Monitor Exacerbation Risk	12.420	HT94252410249	633,056	252,423
<i>Pass Through: University of Florida</i>				
QUantifiEd Coronary Artery Plaque and Outcomes (QUIET): WARR	12.420	SUB00004250	49,478	-
			<u>1,363,594</u>	<u>284,738</u>
TOTAL RESEARCH AND DEVELOPMENT CLUSTER EXPENDITURES			<u>30,792,398</u>	<u>3,387,869</u>

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025
(Continued)**

<u>Federal Grantor/Pass-Through Grantor</u>	<u>Assistance Listing</u>	<u>Agency or Pass-Through Number</u>	<u>Federal Expenditures</u>	<u>Subcontract Expenditures</u>
OTHER PROGRAMS				
<i>US DEPARTMENT OF AGRICULTURE</i>				
<i>Pass Through: State of California WIC Program</i>				
WIC Supplemental Nutrition Program	10.557	25-10180	4,520,686	-
WIC BFPC Loving Support Program	10.557	25-10180	163,905	-
WIC Farmers' Market Nutrition Program	10.557	25-10180	8,244	-
WIC Books for Kids	10.557	25-10180	52,416	-
WIC Supplemental Nutrition Program	10.557	25-10180	10,845,218	-
WIC BFPC Loving Support Program	10.557	25-10180	550,260	-
WIC Local Vendor Liaison	10.557	25-10180	84,076	-
		Total Other Programs	<u>16,224,805</u>	<u>-</u>
TOTAL FEDERAL EXPENDITURES			\$ 47,017,203	\$ 3,387,869

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**NOTES TO THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

NOTE 1 – Basis of Presentation

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (the Institute), formerly known as Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, is an independent biomedical research institute.

The accompanying schedule of expenditures of federal awards (the Schedule) is prepared on the accrual basis of accounting. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the basic financial statements.

NOTE 2 – Summary of Significant Accounting Policies

Expenditures on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement.

NOTE 3 – Indirect Cost Rate

The Institute has elected not to use the de minimis indirect cost rate as allowed under the Uniform Guidance.

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE YEAR ENDED JUNE 30, 2025**

SECTION I – SUMMARY OF AUDITORS’ RESULTS

Financial Statements

The independent auditors’ report expresses an unmodified opinion on whether the financial statements of the Institute were prepared in accordance with generally accepted accounting principles.

Internal control over financial reporting

Material weakness(es) identified? – No

Significant deficiencies identified? – No

Noncompliance material to financial statements noted? – No

Federal Awards

Internal control over major programs

Material weakness(es) identified? – No

Significant deficiencies identified? – None reported

Type of auditors’ report issued on compliance for major programs? – Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR section 200.516(a)? – No

Identification of major programs: Research and Development Cluster with various Assistance Listing Numbers

Dollar threshold used to distinguish between Type A and Type B programs was \$1,410,516

Auditee qualified as low-risk auditee? – Yes

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE YEAR ENDED JUNE 30, 2025**

SECTION II – FINDINGS – FINANCIAL STATEMENT AUDIT

None

**SECTION III – FINDINGS AND QUESTIONED COSTS – MAJOR FEDERAL AWARD PROGRAM
AUDIT**

None

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS
FOR THE YEAR ENDED JUNE 30, 2025**

FINDINGS – FINANCIAL STATEMENT AUDIT

The following item is considered to be a significant deficiency:

2024-01 Prior-Financial Close

Condition:	<p>As part of the audit, there were several adjustments to recognize additional expenses, indicating that certain close processes may not have been working as designed throughout the fiscal year.</p> <p>The adjustments recorded during the audit period include:</p> <ul style="list-style-type: none">• Accruing for disbursements paid after year-end, where services or goods were received prior to year-end;• Accrued employee benefits and related expense were understated by approximately \$500,000;• Payables for accrued retirement contributions were understated by approximately \$900,000; <p>Additionally, clean-up of various accounts that impact prior periods was noted, indicating that controls appear to have not been operating as designed throughout the year, requiring significant time and effort at year-end to complete the close and present accurate and complete financial statements.</p>
Criteria:	<p>Management is responsible for maintaining internal controls to ensure revenue and expenses are recorded in the proper period.</p>
Status:	<p>Financial close processes have improved and this is not considered a recurring finding.</p>

**LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
AT HARBOR-UCLA MEDICAL CENTER**

**SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS
FOR THE YEAR ENDED JUNE 30, 2025**

FINDINGS – FINANCIAL STATEMENT AUDIT (Continued)

2024-02 Prior-SEFA Reporting

Condition: The Institute receives grants and contracts from a variety of sources. Tracking and reporting the transactions tied to these grants and contracts is complex and requires scrutiny of transactions for proper recognition and proper reporting. As part of the audit, there were several adjustments to the schedule of federal expenditures (SEFA) for the year ended June 30, 2024. It was noted during the audit that underlying schedules supporting the SEFA did not tie out to the SEFA. Upon further review, it was determined that significant updates were required to be made to the SEFA, which resulted in additional reported expenditures.

Criteria: Section 2 CFR 200.510(b) of the Uniform Guidance requires that an auditee prepare a SEFA, which includes individual federal programs by federal agency and total federal awards expended for each individual federal program and Assistance Listing Number. Management is responsible for establishing and maintaining an effective system of internal control to allow for complete and accurate preparation of the SEFA.

Status: Management’s corrective actions in 2025 included implementing a more robust process to prepare and review an accurate and complete SEFA report; this finding is not repeated.